1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
About Peanut Allergy
Peanut allergy is one of the most common types of food allergies that results in itchiness, abdominal pain, swelling, sneezing, diarrhea, and cardiac arrest. The analysts forecast the Global Peanut Allergy Market to grow at a CAGR of 89.68% during the period 2019-2023.
Covered in this report
The report covers the present scenario and the growth prospects of the peanut allergy market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of peanut allergy across the globe.
The market is divided into the following segments based on geography:
The report, peanut allergy market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendor
Market drivers
Market challenges
Market trends
Key questions answered in this report
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Peanut allergy is one of the most common types of food allergies that results in itchiness, abdominal pain, swelling, sneezing, diarrhea, and cardiac arrest. The analysts forecast the Global Peanut Allergy Market to grow at a CAGR of 89.68% during the period 2019-2023.
Covered in this report
The report covers the present scenario and the growth prospects of the peanut allergy market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of peanut allergy across the globe.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
The report, peanut allergy market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendor
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
Market drivers
- Increase in collaborations for R&D
- For a full, detailed list, view the full report
Market challenges
- Avoiding the consumption of peanuts
- For a full, detailed list, view the full report
Market trends
- Business strategy framework in form of spin-offs
- For a full, detailed list, view the full report
Key questions answered in this report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORTPART 06: PIPELINEPART 08: CUSTOMER LANDSCAPEPART 10: DECISION FRAMEWORKPART 12: MARKET TRENDSPART 16: About the Author
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCT
PART 09: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
PART 15: APPENDIX
List of Exhibits
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
Global Peanut Allergy Market 2019-2023
The author of the report recognizes the following company as the key player in the global peanut allergy market: Aimmune Therapeutics, Aravax, DBV Technologies, HAL Allergy, and Immunomic Therapeutics.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is the business strategy framework in form of spin-offs. Spin-offs are done by companies to increase the focus on emerging businesses or for technologies that have the potential to disrupt the market. Universities and research institutes are also following this strategy to develop novel therapies to treat various indications.”
According to the report, one driver influencing this market is the driven by the increase in collaborations for R&D. Drug development and marketing is an expensive and lengthy affair in the pharmaceutical industry as the peanut allergy therapy companies need extensive funding, advanced manufacturing units, and a strong distribution network. Several peanut allergy therapy companies are engaging in collaborations to gain a strong foothold on funds and skill set to develop novel peanut allergy treatment methods.
Further, the report states that one challenge affecting this market is avoiding the consumption of peanuts. The occurrence of peanut allergy is one of the rapidly increasing allergies in developed countries and is usually life-long once acquired, and the avoidance of consumption of peanuts is expected to hamper the market growth.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following company as the key player in the global peanut allergy market: Aimmune Therapeutics, Aravax, DBV Technologies, HAL Allergy, and Immunomic Therapeutics.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is the business strategy framework in form of spin-offs. Spin-offs are done by companies to increase the focus on emerging businesses or for technologies that have the potential to disrupt the market. Universities and research institutes are also following this strategy to develop novel therapies to treat various indications.”
According to the report, one driver influencing this market is the driven by the increase in collaborations for R&D. Drug development and marketing is an expensive and lengthy affair in the pharmaceutical industry as the peanut allergy therapy companies need extensive funding, advanced manufacturing units, and a strong distribution network. Several peanut allergy therapy companies are engaging in collaborations to gain a strong foothold on funds and skill set to develop novel peanut allergy treatment methods.
Further, the report states that one challenge affecting this market is avoiding the consumption of peanuts. The occurrence of peanut allergy is one of the rapidly increasing allergies in developed countries and is usually life-long once acquired, and the avoidance of consumption of peanuts is expected to hamper the market growth.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
Note: Product cover images may vary from those shown
